02.27.24
In Nested Bean, Inc. v. Big Beings USA Pty Ltd.,1 the director of the 'U.S. Patent and Trademark Office (Patent Office) (Director) granted review and modified the Patent Trial and Appeal Board’s (Board) final written decision (Final Written Decision) to require the Board to consider ...
Seamless and secure data exchange that prioritizes the surfacing of critical and actionable insights early, often and in an accessible format is vital for digitally enabled care.
In January 2024, the U.S. Government Accountability Office (GAO) issued a report highlighting current obstacles to the U.S. Food and Drug Administration’s (FDA) timely and effective regulation of artificial intelligence (AI) and machine learning (ML) in medical devices and other emerging ...
02.25.24
In a new webinar with frontline clinicians and policymakers, the AMA and Manatt Health will discuss the recommendations in depth and highlight state- and community-based best practices.
02.22.24
Apparently in light of recent litigation against Medicare Advantage (MA) plans, on February 6, 2024, CMS published responses to frequently asked questions (FAQs) regarding the use of algorithms and artificial intelligence in coverage determinations.
02.21.24
On February 16, 2024, the Consumer Financial Protection Bureau (CFPB) issued a procedural rule revising its supervisory appeals process for the first time since 2015.
On January 9, 2024, the Centers forMedicare and Medicaid Services (CMS) approved New York’s request to amend its Medicaid section 1115 demonstration waiver, “Medicaid Redesign Team.
02.20.24
The United States Patent and Trademark Office (USPTO) and the Court of Appeals for the Federal Circuit have both previously held that an artificial intelligence (AI) system cannot be a sole inventor on a patent application since each inventor must be a human being.
02.13.24
In Xerox Corp. v. Bytemark, Inc., the Director of the U.S. Patent and Trademark Office made precedential a prior decision of the Patent Trial and Appeal Board (the Board) over when an expert declaration from an inter partes review (IPR) should be afforded little weight.
To date, the Centers for Medicare & Medicaid Services (CMS) has approved nearly 400 section 1902(e)(14) waivers that 52 states (including Washington D.C.) and territories are employing to support the return to regular eligibility and enrollment operations following the expiration of the ...